Compare OPRA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | MPLT |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | Norway | United States |
| Employees | N/A | 133 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2018 | N/A |
| Metric | OPRA | MPLT |
|---|---|---|
| Price | $19.29 | $38.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $21.50 | ★ $32.67 |
| AVG Volume (30 Days) | 335.1K | ★ 477.1K |
| Earning Date | 04-28-2026 | 05-28-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.29 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | $13.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.71 | $12.24 |
| 52 Week High | $21.06 | $39.91 |
| Indicator | OPRA | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.61 | 65.36 |
| Support Level | $16.96 | $26.20 |
| Resistance Level | $19.43 | N/A |
| Average True Range (ATR) | 0.71 | 2.80 |
| MACD | -0.02 | 0.66 |
| Stochastic Oscillator | 51.41 | 83.61 |
Opera Ltd is a consumer internet software company providing a diversified portfolio of high-performance web browsers and adjacent digital services to engaged user base The company has transitioned from browser developer to multi-faceted platform offering a products and services that include PC and mobile browsers, its Opera Gaming portals and development tools, Opera News content platforms, Opera Ads platform, as well as a number of AI and web3 products and services, such as MiniPay and Opera AI, to a user base.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.